Physician profile
Roger W Newsom
NPI 1134139975
$5,134.88
in general payments reported to CMS, 2019-2025
29 companies · $1,119 in 2025
The $1,119 reported for 2025 was more than what 79% of Ophthalmic Plastic and Reconstructive Surgery providers received nationally (typical 2025 total: $299).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $974 · 2020: $868 · 2021: $212 · 2022: $533 · 2023: $710 · 2024: $719 · 2025: $1,119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,548.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,547.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,435.55 | 2019-2025 | Clareon, Argos, Eysuvis |
| Allergan, INC. | $1,001.88 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $417.44 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $361.69 | 2019-2025 | Cequa |
| Abbvie INC. | $330.51 | 2022-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $240.67 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $196.00 | 2019-2023 | |
| Aerie Pharmaceuticals, INC. | $152.63 | 2019 | |
| Mallinckrodt Hospital Products INC. | $144.35 | 2025 | Acthar |
| Sight Sciences, INC. | $115.85 | 2019 | |
| Ocular Therapeutix, INC. | $89.20 | 2019 | |
| Rxsight INC | $83.94 | 2024 | Rxsight Injector Cartridge, Rxsight Contact Lens, Light Adjustable Lens (Lal) |
| Rayner Intraocular Lenses Limited | $58.88 | 2023-2025 | Rayone Spheric, Rayone Emv, Rayone Aspheric |
| Harrow Eye, LLC | $58.13 | 2025 | Vevye |
| Oyster Point Pharma, INC. | $56.97 | 2022-2023 | Tyrvaya |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $52.79 | 2022-2025 | Xiidra, Miebo, Prolensa |
| Merz Pharmaceuticals, LLC | $47.87 | 2025 | Xeomin |
| Kala Pharmaceuticals, INC. | $40.84 | 2019 | |
| Oasis Medical, INC. | $39.10 | 2019 | |
| Carl Zeiss Meditec Cataract Technology INC. | $29.86 | 2023 | |
| Mallinckrodt Enterprises LLC | $27.45 | 2019 | |
| Horizon Therapeutics Plc | $24.40 | 2022 | |
| Biotissue Holdings INC. | $21.36 | 2023 | |
| Biogen, INC. | $20.72 | 2023 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Amgen INC. | $18.74 | 2025 | Tepezza |
| New World Medical,INC. | $17.09 | 2023 | |
| Eyevance Pharmaceuticals LLC | $16.59 | 2020 | |
| Johnson & Johnson Surgical Vision, INC. | $14.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roger Newsom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.